Miranda Pans

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study

Robert Kerwin, Bruno Millet, Erik Herman et al. · European Psychiatry · 2007 · 108 citations

A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)

Rajiv Tandon, Ronald N. Marcus, Elyse Stock et al. · Schizophrenia Research · 2006 · 108 citations

Psychiatry, Psychotic Disorder, Medicine +10

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)

Linda Hanssens, Gilbert L’Italien, Jean‐Yves Loze et al. · BMC Psychiatry · 2008 · 83 citations · Full text

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)

Jeffrey Kaine, Geoffrey Gladstein, Ingrid Strusberg et al. · Annals of the Rheumatic Diseases · 2011 · 73 citations · Full text

Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage^® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies

Ken Fujioka, Ronald Brazg, Itamar Raz et al. · Diabetes Obesity and Metabolism · 2004 · 71 citations